Ergocalciferol and Ampyra drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among people who take Ergocalciferol (ergocalciferol) and Ampyra (dalfampridine). Common drug interactions include multiple sclerosis relapse among females and fall among males.
The phase IV clinical study analyzes what interactions people have when they take Ergocalciferol and Ampyra. It is created by eHealthMe based on reports of 263 people who take the same drugs from the FDA, and is updated regularly.
What is Ergocalciferol?
Ergocalciferol has active ingredients of ergocalciferol. It is often used in rickets. eHealthMe is studying from 32,652 Ergocalciferol users. Check the latest studies of Ergocalciferol.
What is Ampyra?
Ampyra has active ingredients of dalfampridine. It is often used in multiple sclerosis. eHealthMe is studying from 77,145 Ampyra users. Check the latest studies of Ampyra.
263 people who take Ergocalciferol and Ampyra together, and have interactions are studied.
What are the common drug interactions of Ergocalciferol and Ampyra, by gender? *
What are the common drug interactions of Ergocalciferol and Ampyra, by age (0-1 to 60+)? *
What are the existing conditions these people have? *
* Approximation only. Some reports may have incomplete information.
Do you take Ergocalciferol and Ampyra?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
- Ergocalciferol (32,652 reports)
- Ampyra (77,145 reports)
Browse all drug interactions of Ergocalciferol and Ampyra:
a b c d e f g h i j k l m n o p q r s t u v w x y zSub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Ergocalciferol:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Ampyra:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Ergocalciferol and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Ampyra and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zRelated publications that referenced our studies
- Kapoor S, "Influence of Vitamin D Consumption and Levels on the Development of Psychiatric Disorders", Lee, Y. J., & Park, K. (2018). Secondary Raynaud’s Phenomenon and Skin Necrosis of Toes in the Paraplegic Patient with Hypertension.?Drug safety-case reports,?5(1), 7., 2014 Aug .
- Kapoor S, "Influence of Vitamin D Consumption and Levels on the Development of Psychiatric Disorders", Lee, Y. J., & Park, K. (2018). Secondary Raynaud’s Phenomenon and Skin Necrosis of Toes in the Paraplegic Patient with Hypertension.?Drug safety-case reports,?5(1), 7., 2014 Aug .
How the study uses the data?
The study uses data from the FDA. It is based on ergocalciferol and dalfampridine (the active ingredients of Ergocalciferol and Ampyra, respectively), and Ergocalciferol and Ampyra (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Nexium cause Procedural Haemorrhage? - 3 seconds ago
- Isosorbide Dinitrate vs. Aspirin, side effect and effectiveness comparison - 5 seconds ago
- Could Hydroxyzine Pamoate cause Back Pain Aggravated? - 11 seconds ago
- Could Fosamax cause Vasculitis? - 12 seconds ago
- Could Toradol cause Nerve Injury? - 13 seconds ago
- Could Robitussin cause Acute Respiratory Failure? - 13 seconds ago
- Could Septocaine cause Deep Venous Thrombosis? - 17 seconds ago
- Could Remodulin cause Injection Site Pustule? - 18 seconds ago
- Could Xanax cause Cyst? - 19 seconds ago
- Could Fosamax cause Atrophy? - 22 seconds ago